Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

NCT02287129 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Esophagogastric Junction

Interventions

DRUG: Oxaliplatin
DRUG: Epirubicin
DRUG: Capecitabine
DRUG: 5-FU
DRUG: Carboplatin
DRUG: Paclitaxel
RADIATION: radiation
PROCEDURE: Biopsy

Sponsor

Technical University of Munich